Curaleaf: Revenue Growth Has Returned, But Margin Compression Keeps The Rating At Hold

Curaleaf (OTCQX: CURLF / TSX: CURA) posted 10% year-over-year revenue growth in the second quarter of 2026, marking its second consecutive quarter of U.S. domestic revenue growth after a stretch of annual declines. Gross margin expanded to 50%, up 70 basis points from the prior year. The company turned profitable on a GAAP basis, reporting $12.5 million in net income versus a $50.6 million loss in Q2 2025. The federal government rescheduled cannabis to Schedule III in April, removing the most extreme regulatory overhang that has weighed on the sector.

Despite all of that, the stock fell $0.42 to $1.63 on the earnings release. The market is voting with its feet: the growth reacceleration is real, but the margin profile and balance sheet still carry enough risk to keep the rating at Hold. The valuation has moved into a defensible range, but it is not yet cheap enough to absorb further execution misses.

What changed

Revenue came in at $340.1 million, up 10% from $310.6 million a year earlier and up 5% sequentially from Q1 2026. The domestic segment grew 7% and the international segment grew 26%, with international revenue reaching $51 million. Both legs are moving in the right direction. The U.S. business is past the bottom.

Gross margin of 50% improved from 49% a year ago, which is a positive signal in a category where many cannabis operators are still battling pricing pressure and promotional discounting. Curaleaf also launched Dark Heart, an ultra-premium flower brand, across 11 states, which suggests management is pushing up the quality ladder rather than fighting on price alone.

Where the quarter stumbles is adjusted EBITDA - earnings before interest, taxes, depreciation, and amortization, a rough proxy for operating cash generation. Adjusted EBITDA was $70.1 million, which sounds healthy until you look at the margin. At 20.6% of revenue, the adjusted EBITDA margin declined 120 basis points year-over-year. Revenue grew 10%, but cash earnings barely grew from the $65.5 million run rate a year ago. That divergence is what spooked investors. Growth that does not translate into margin expansion raises the question of whether the revenue gains are coming with heavier cost, more discounting, or lower-margin product mix.

The balance sheet picture

Curaleaf ended Q2 with $107 million in cash. The company closed a $500 million senior secured note in Q1 and used it to refinance maturing debt. That keeps the lights on, but it also means interest expense is front-loaded. At a $2.34 billion market cap and roughly $3.07 billion enterprise value, the company is carrying significant leverage relative to its cash generation. Free cash flow in Q1 was $4.3 million; Q2 free cash flow figures were not broken out in the earnings release. Without seeing whether cash conversion is improving alongside top-line growth, the balance sheet remains a constraint.

Valuation: defensible, not cheap

Annualizing Q2 results, the stock trades at roughly 1.7 times revenue and about 11 times adjusted EBITDA. That is not the kind of multiple that demands euphoric growth. It is the kind of multiple that says investors need to see the operating improvements hold, not just appear for one quarter.

The first half of 2026 tells a similar story. Revenue was $664.3 million, up 8% year-over-year, with adjusted EBITDA of $133.5 million on a 20.1% margin, down 100 basis points from the prior-year period. Two quarters in a row of revenue growth are a turnaround signal. Two quarters in a row of EBITDA margin compression are a warning sign.

The regulatory tailwind

The DOJ's April 23 order placing state-licensed medical cannabis into Schedule III is a structural change, not a cosmetic one. Curaleaf filed DEA registration applications for its cultivation, processing, and dispensing locations, putting it ahead of the curve. Schedule III status unlocks deductibility for federal tax purposes, eases banking access, and opens a path to broader interstate commerce - each of which would materially improve economics for state-licensed operators.

But the practical timeline is still uncertain. An expedited administrative hearing on broader rescheduling begins June 29, 2026. The full rulemaking process will take additional time, and the near-term financial impact depends on how quickly tax deductibility and banking normalization actually materialize. The tailwind is real but distant enough that investors should not price it in as if it has already happened.

What would change the rating

An upgrade requires three things to converge:

1. A third consecutive quarter of U.S. domestic revenue growth with EBITDA margin at or above 21%, confirming that top-line gains are not coming at the expense of profitability.
2. Visible improvement in free cash flow, showing that growth is converting to cash rather than sitting in inventory or working capital.
3. Evidence that the DEA registration and Schedule III framework are reducing tax drag or unlocking better financing terms.

A downgrade would follow if revenue growth slows below 5% year-over-year, if EBITDA margins compress further below 20%, or if the company needs to raise capital at unfavorable terms to maintain its cash runway.

Verdict: Hold

Curaleaf is doing the things it needed to do. Revenue is back in positive territory, gross margins are expanding, and the regulatory environment is improving. But the margin compression in the quarter, the heavy debt load relative to cash generation, and the absence of a free cash flow breakout mean the risk/reward does not yet support a Buy. The stock at $1.63 is defensible for investors already on board, but new capital is better positioned once the next earnings release confirms that the margin profile is stabilizing alongside the revenue recovery.

Two good quarters are a start. Three is a trend.